128510-88-3 Usage
Description
(R)-TERT-BUTYL 2-(TOSYLOXYMETHYL)PYRROLIDINE-1-CARBOXYLATE is a chemical compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique structure and reactivity, which makes it a valuable component in the development of drugs for different medical conditions.
Uses
Used in Pharmaceutical Synthesis:
(R)-TERT-BUTYL 2-(TOSYLOXYMETHYL)PYRROLIDINE-1-CARBOXYLATE is used as an intermediate in the synthesis of (2S)-Ethylpyrrolidine Hydrochloride (E818080) for the treatment of Alzheimer's disease. It plays a crucial role in the development of this drug, contributing to its effectiveness in managing the cognitive decline associated with the condition.
Used in Alzheimer's Disease Treatment:
In the pharmaceutical industry, (R)-TERT-BUTYL 2-(TOSYLOXYMETHYL)PYRROLIDINE-1-CARBOXYLATE is used as a reagent in the synthesis of N,N''-substituted-1,3-diamino-2-hydroxypropanes. These compounds are integral in the development of drugs aimed at treating Alzheimer's disease, providing potential therapeutic benefits for patients suffering from this neurodegenerative condition.
Used in JAK Kinase Inhibitors Synthesis:
(R)-TERT-BUTYL 2-(TOSYLOXYMETHYL)PYRROLIDINE-1-CARBOXYLATE is also used as a reagent in the synthesis of cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives. These compounds act as JAK kinase inhibitors, which are utilized in the treatment of various diseases, including autoimmune diseases, cancer, and inflammatory conditions. The compound's role in this process highlights its importance in the development of targeted therapies for a range of medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 128510-88-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,5,1 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 128510-88:
(8*1)+(7*2)+(6*8)+(5*5)+(4*1)+(3*0)+(2*8)+(1*8)=123
123 % 10 = 3
So 128510-88-3 is a valid CAS Registry Number.
InChI:InChI=1/C17H25NO5S/c1-13-7-9-15(10-8-13)24(20,21)22-12-14-6-5-11-18(14)16(19)23-17(2,3)4/h7-10,14H,5-6,11-12H2,1-4H3
128510-88-3Relevant articles and documents
Synthesis and Stereochemical Assignment of Conioidine A: DNA- And HSA-Binding Studies of the Four Diastereomers
Shaktah, Ryan,Vardanyan, Laura,David, Elroma,Aleman, Alexis,Orr, Dupre,Shaktah, Lawrence A.,Tamae, Daniel,Minehan, Thomas
supporting information, p. 3191 - 3198 (2020/11/03)
Conioidine A (1), isolated in 1993 with unknown relative and absolute configuration, was suggested to be a DNA-binding compound by an indirect technique. Four stereoisomers of conioidine A have been synthesized from d- and l-proline, and the natural product has been identified as possessing (4R,6R) absolute configuration. Binding of the conioidine diastereomers to calf thymus DNA (CT DNA) and human serum albumin (HSA) has been investigated by fluorescence spectroscopy and isothermal titration calorimetry (ITC). All stereoisomers display at least an order of magnitude weaker binding to DNA than the control compound netropsin; however, a strong association with HSA was observed for the (4R,6S) stereoisomer.
AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF
-
Paragraph 0283, (2018/12/02)
The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.
FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME
-
Paragraph 00208, (2017/03/08)
Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
